Overtake us the second, “autumn”, the wave of the coronavirus that causes it is not known yet. However, to prepare for it it is necessary – in this doctors around the world agree. And proper training must include routine, annual vaccination against seasonal influenza, and this can significantly reduce the risk of infection with influenza, acute respiratory viral infections and their severe course. Therefore, the choice of flu vaccine is now becoming very relevant: adjuvant or stadyumunda, imported or Russian?
The question of which vaccine is more effective – adjuvant or bazazyants – is still a matter of controversy.
Doctor of medical Sciences, specialist on vaccine prevention Professor Mikhail Kostinov came to the conclusion that the flu vaccine “Grippol plus” containing adjuvant anoxemia bromide (“Polyoxidonium”), there are clear advantages over bezeljanskii vaccines. The evidence he presented in the scientific article for the international journal Frontiers in Immunology-Vaccines and Molecular Therapeutics.
Adjuvant is a compound or complex of substances, which are used to enhance the immune response upon introduction simultaneously with the antigen. The inclusion of adjuvants in vaccines is one of the main directions recommended by the world health organization, to improve products.
Antigen-saving strategy, in which the use of adjuvants, allows you to quickly immunize the population. According to experts, this is especially important against the background of the new coronavirus pandemic and future pandemics, which will inevitably face humanity.
The study, which is discussed in the article, has convincingly demonstrated that the vaccine with adjuvant anoxemia bromide better activates other molecules necessary for immune processes in the body.
In his work Mikhail Kostinov and his colleagues analyzed the effect of influenza vaccines with adjuvants without it on the cytokine profile of mononuclear leukocytes of women aged 18 to 40, who throughout his life did not make shots. In total, the study involved three drugs: Russian adjuvant vaccine (Grippol plus) and two foreign vaccines (influvak, Vaksihryp).
All vaccines used in the study, activated cellular immune response. First place in activity took immunoadjuvant vaccine, split vaccine – second place, subunit vaccine showed minimal effectiveness. This is achieved by a component of the vaccine – adjuvant anoxemia bromide (Polyoxidonium).
As reported by “Rambler”, “Polyoxidonium”, which is used as a standalone drug for the prevention of acute respiratory infections in April were included in the interim recommendations of the Ministry of health for Lethe inclusion of SARS in a pandemic COVID-19.
The President of “Petrovax” (the company produces vaccines against influenza with the adjuvant anoxemia bromide) Michael Cyferov told “Kommersant” that the company launched an international multicentre clinical trial of the drug among patients with the new coronavirus, which experts will evaluate the efficacy and safety of “Polyoxidonium” for infected patients aged 18 to 85 years.
